Use of varenicline for 4 weeks before quitting smoking: decrease in ad lib smoking and increase in smoking cessation...

Area of Science:

• Clinical Medicine
• Pharmacology
• Addiction Research

Background:

• Varenicline tartrate aids smoking cessation by reducing withdrawal and smoking reward.
• Current protocols start varenicline one week pre-quit, potentially limiting efficacy.
• Investigating extended pre-quit varenicline duration to enhance smoking cessation outcomes.

Purpose of the Study:

• To determine if a longer pre-quit varenicline period reduces smoking satisfaction and improves quit rates.
• To assess the impact of varenicline preloading on smoking behavior and abstinence.
• To evaluate the safety and tolerability of extended varenicline use.

Main Methods:

• 101 smokers were randomized to receive varenicline for 4 weeks or placebo for 3 weeks followed by 1 week of varenicline before quitting.
• Standard 3-month varenicline treatment followed the initial period for both groups.
• Measurements included pre-quit smoking satisfaction, smoke intake, post-quit urges, withdrawal, and 12-week sustained abstinence.

Main Results:

• Varenicline preloading significantly decreased pre-quit smoking enjoyment and smoke intake.
• 12-week abstinence rates were higher in the varenicline preloading group (47.2%) versus placebo (20.8%).
• The benefit was pronounced in participants who reduced cotinine levels by over 50% ('reducers').

Conclusions:

• Extended varenicline preloading effectively reduces ad lib smoking and boosts 12-week quit rates.
• Current standard varenicline treatment schedules may be suboptimal for smoking cessation.
• Further trials with longer follow-up are recommended to confirm these findings.